Clearing up misunderstandings around core outcomes for atopic dermatitis

H. C. Williams; C. Apfelbacher; J. R. Chalmers; J. Schmitt; E. L. Simpson; P. I. Spuls; K. S. Thomas

doi:https://doi.org/10.1111/bjd.13787

Clearing up misunderstandings around core outcomes for atopic dermatitis

H. C. Williams, C. Apfelbacher, J. R. Chalmers, J. Schmitt, E. L. Simpson, P. I. Spuls, K. S. Thomas

Research output: Contribution to journal › Comment/Letter to the editor › Academic

1 Citation (Scopus)

Abstract

We thank Professor Taieb for his comments on the report of the Third International Consensus Meeting to Harmonise Core Outcome Measures for Atopic Eczema/Dermatitis Clinical Trials (HOME III) in the December 2014 issue of the BJD (1). He promulgates a number of misconceptions about our work which we wish to respond to. First, he suggests that the Outcome Measures in Rheumatology (OMERACT) filter "truth, discrimination and feasibility" might not be applicable to outcome measurement instruments for atopic dermatitis (AD) (2). This article is protected by copyright. All rights reserved

Original language	English
Pages (from-to)	623-4; discussion 624-5
Journal	British Journal of Dermatology
Volume	173
Issue number	2
DOIs	https://doi.org/10.1111/bjd.13787
Publication status	Published - 2015

Access to Document

https://doi.org/10.1111/bjd.13787

Cite this

@article{1525065eef5045b18f87913b224d9841,

title = "Clearing up misunderstandings around core outcomes for atopic dermatitis",

abstract = "We thank Professor Taieb for his comments on the report of the Third International Consensus Meeting to Harmonise Core Outcome Measures for Atopic Eczema/Dermatitis Clinical Trials (HOME III) in the December 2014 issue of the BJD (1). He promulgates a number of misconceptions about our work which we wish to respond to. First, he suggests that the Outcome Measures in Rheumatology (OMERACT) filter {"}truth, discrimination and feasibility{"} might not be applicable to outcome measurement instruments for atopic dermatitis (AD) (2). This article is protected by copyright. All rights reserved",

author = "Williams, {H. C.} and C. Apfelbacher and Chalmers, {J. R.} and J. Schmitt and Simpson, {E. L.} and Spuls, {P. I.} and Thomas, {K. S.}",

year = "2015",

doi = "https://doi.org/10.1111/bjd.13787",

language = "English",

volume = "173",

pages = "623--4; discussion 624--5",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Clearing up misunderstandings around core outcomes for atopic dermatitis

AU - Williams, H. C.

AU - Apfelbacher, C.

AU - Chalmers, J. R.

AU - Schmitt, J.

AU - Simpson, E. L.

AU - Spuls, P. I.

AU - Thomas, K. S.

PY - 2015

Y1 - 2015

N2 - We thank Professor Taieb for his comments on the report of the Third International Consensus Meeting to Harmonise Core Outcome Measures for Atopic Eczema/Dermatitis Clinical Trials (HOME III) in the December 2014 issue of the BJD (1). He promulgates a number of misconceptions about our work which we wish to respond to. First, he suggests that the Outcome Measures in Rheumatology (OMERACT) filter "truth, discrimination and feasibility" might not be applicable to outcome measurement instruments for atopic dermatitis (AD) (2). This article is protected by copyright. All rights reserved

AB - We thank Professor Taieb for his comments on the report of the Third International Consensus Meeting to Harmonise Core Outcome Measures for Atopic Eczema/Dermatitis Clinical Trials (HOME III) in the December 2014 issue of the BJD (1). He promulgates a number of misconceptions about our work which we wish to respond to. First, he suggests that the Outcome Measures in Rheumatology (OMERACT) filter "truth, discrimination and feasibility" might not be applicable to outcome measurement instruments for atopic dermatitis (AD) (2). This article is protected by copyright. All rights reserved

U2 - https://doi.org/10.1111/bjd.13787

DO - https://doi.org/10.1111/bjd.13787

M3 - Comment/Letter to the editor

C2 - 25819300

SN - 0007-0963

VL - 173

SP - 623-4; discussion 624-5

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 2

ER -